Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals Inc (NQ: TARS )

25.01 -3.23 (-11.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,935,104
Open 28.35
Bid (Size) 25.25 (1)
Ask (Size) 25.49 (1)
Prev. Close 28.24
Today's Range 23.73 - 28.82
52wk Range 12.57 - 42.50
Shares Outstanding 20,574,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire

Performance

YTD
+24.06%
+24.06%
1 Month
-3.10%
-3.10%
3 Month
-22.35%
-22.35%
6 Month
-4.72%
-4.72%
1 Year
+25.87%
+25.87%

More News

Read More
Analyst Ratings For Tarsus Pharmaceuticals
Via Benzinga
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) is a Stock Spotlight on 4/15
Via Investor Brand Network
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Simple Ways To Stay With Trends: The Week In Charts
Via Talk Markets
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
Tarsus Pharmaceuticals's Earnings: A Preview
Via Benzinga
Tarsus Pharmaceuticals - Mixed Projections
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Participate at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Announces Pricing of $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Announces Proposed $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.